A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and
intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors).
This research study is the first time that AG-024322 will be given to people.